MiNA Therapeutics is the global leader in small activating RNA therapeutics or RNAa. Harnessing innate mechanisms of gene activation, RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.
We are advancing a proprietary pipeline of new medicines with an initial focus on genetic medicine, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of other therapeutic areas.
NEW CLASS OF MEDICINES
Small activating RNA (RNAa) therapeutics are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.
CLINICAL STAGE PLATFORM
We have developed a systematic approach to take new RNAa medicines from an idea to patients in a clinical trial in just 2 years.
Driving our platform are a group of passionate scientists, drug developers and entrepreneurs shaped by experience in oligonucleotide therapeutics and translating scientific breakthroughs to patients.